Document Detail

Transforming growth factor beta in hypertensives with cardiorenal damage.
MedLine Citation:
PMID:  11040229     Owner:  NLM     Status:  MEDLINE    
We investigated whether a relationship exists between circulating transforming growth factor beta -1 (TGF-beta(1)), collagen type I metabolism, microalbuminuria, and left ventricular hypertrophy in essential hypertension and whether the ability of the angiotensin II type 1 receptor antagonist losartan to correct microalbuminuria and regress left ventricular hypertrophy in hypertensives is related to changes in TGF-beta(1) and collagen type I metabolism. The study was performed in 30 normotensive healthy controls and 30 patients with never-treated essential hypertension classified into 2 groups: those with microalbuminuria (urinary albumin excretion >30 and <300 mg/24 h) associated with left ventricular hypertrophy (left ventricular mass index >116 g/m(2) for men and >104 g/m(2) for women) (group B; n=17) and those without microalbuminuria or left ventricular hypertrophy (group A; n=13). The measurements were repeated in all patients after 6 months of treatment with losartan (50 mg once daily). The serum concentration of TGF-beta(1) was measured by a 2-site ELISA method, and the serum concentrations of carboxy-terminal propeptide of procollagen type I (a marker of collagen type I synthesis) and carboxy-terminal telopeptide of collagen type I (a marker of collagen type I degradation) were measured by specific radioimmunoassays. The duration of hypertension and baseline values of blood pressure were similar in the 2 groups of patients. No differences in serum TGF-beta(1), carboxy-terminal propeptide of procollagen type I, and carboxy-terminal telopeptide of collagen type I were found between normotensives and group A of hypertensives. Serum TGF-beta(1), carboxy-terminal propeptide of procollagen type I, and the ratio of carboxy-terminal propeptide of procollagen type I to carboxy-terminal telopeptide of collagen type I were increased (P<0.05) in group B of hypertensives compared with group A of hypertensives and normotensives. No differences in carboxy-terminal telopeptide of collagen type I were found among the 3 groups of subjects. After treatment with losartan, microalbuminuria and left ventricular hypertrophy persisted in 6 patients (then considered nonresponders) and disappeared in 11 patients (then considered responders) from group B. Compared with nonresponders, responders exhibited similar control of blood pressure and higher (P<0.05) blockade of angiotensin II type 1 receptors (as assessed by a higher increase in plasma levels of angiotensin II). Whereas TGF-beta(1), carboxy-terminal propeptide of procollagen type I, and the ratio of carboxy-terminal propeptide of procollagen type I to carboxy-terminal telopeptide of collagen type I decreased (P<0.05) in responders, no changes in these parameters were observed in nonresponders. These findings show that an association exists between an excess of TGF-beta(1), stimulation of collagen type I synthesis, inhibition of collagen type I degradation, and cardiorenal damage in a group of patients with essential hypertension. In addition, our results suggest that the ability of losartan to blunt the synthesis of TGF-beta(1) and normalize collagen type I metabolism may contribute to protect the heart and the kidney in a fraction of patients with essential hypertension.
C Laviades; N Varo; J Díez
Related Documents :
886469 - Leakage of dl-propranolol from cerebrospinal fluid to the bloodstream in the rabbit.
7039899 - The treatment of hypertension by labetalol--a new alpha- and beta-adrenoreceptor blocki...
22885649 - Neurally adjusted ventilatory assist (nava) improves patient-ventilator interaction dur...
6378669 - High-pressure dissociation of the beta 2-dimer of tryptophan synthase from escherichia ...
3154919 - Role of vasodilation in the antihypertensive and antianginal effects of labetalol: impl...
2316229 - Prolonged labetalol infusion for management of severe hypertension and tachycardia in a...
3526789 - Central haemodynamics and oxygen transport during cppv with frequencies of 16 and 8 tim...
11196079 - Occupational exposure to low concentrations of carbon disulfide as a risk factor for hy...
16173489 - Comparison of arterial pressure waveform analysis with the lithium dilution technique t...
Publication Detail:
Type:  Clinical Trial; Controlled Clinical Trial; Journal Article    
Journal Detail:
Title:  Hypertension     Volume:  36     ISSN:  1524-4563     ISO Abbreviation:  Hypertension     Publication Date:  2000 Oct 
Date Detail:
Created Date:  2000-10-25     Completed Date:  2000-11-21     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7906255     Medline TA:  Hypertension     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  517-22     Citation Subset:  IM    
Division of Nephrology, San Jorge General Hospital, Huesca, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Albuminuria / blood*,  complications,  drug therapy,  urine
Angiotensin II / blood
Antihypertensive Agents / therapeutic use
Collagen / blood,  metabolism
Collagen Type I
Hypertension / blood*,  complications,  drug therapy*
Hypertrophy, Left Ventricular / blood*,  complications,  drug therapy
Losartan / therapeutic use*
Middle Aged
Peptide Fragments / blood
Peptides / blood
Procollagen / blood
Transforming Growth Factor beta / blood*
Transforming Growth Factor beta1
Treatment Outcome
Reg. No./Substance:
0/Antihypertensive Agents; 0/Collagen Type I; 0/Peptide Fragments; 0/Peptides; 0/Procollagen; 0/TGFB1 protein, human; 0/Transforming Growth Factor beta; 0/Transforming Growth Factor beta1; 0/collagen type I trimeric cross-linked peptide; 0/procollagen type I carboxy terminal peptide; 11128-99-7/Angiotensin II; 114798-26-4/Losartan; 9007-34-5/Collagen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Important role of angiotensin II-mediated c-Jun NH(2)-terminal kinase activation in cardiac hypertro...
Next Document:  Beneficial renal and hemodynamic effects of omapatrilat in mild and severe heart failure.